Blackfly Investments dba Molecular Testing Labs sells an HIV dried blood spot self-collection kit without FDA marketing authorization.
What happened
FDA reviewed the firm’s website (last reviewed October 1, 2024), prior correspondence, and other information. FDA found that MTL offers an HIV dried blood spot card self-collection kit for delivery to individuals, who are to self-collect samples and ship them to MTL for HIV testing. FDA says the kit has no approved PMA or IDE and no 510(k) notification, and that the firm continued to market it after FDA said it was not authorized.
What FDA found
FDA says the HIV DBS card self-collection kit is a device because it is intended for use in diagnosing disease.
FD&C Act §201(h)(1), 21 U.S.C. §321(h)(1)FDA says the kit is adulterated because it lacks an approved premarket approval application (PMA, FDA review for high-risk devices) or an approved investigational device exemption (IDE, permission to study an unapproved device).
FD&C Act §501(f)(1)(B), 21 U.S.C. §351(f)(1)(B); §§515(a), 520(g)FDA says the kit is misbranded because the firm did not provide the required 510(k) premarket notification before commercial distribution.
FD&C Act §502(o), 21 U.S.C. §352(o); §510(k), 21 U.S.C. §360(k)FDA says it has not authorized the kit for any use, including HIV serological diagnostic testing.
FDA says the firm continued to market the kit after FDA told the firm it had no approved PMA, cleared 510(k), or approved IDE for it.
What FDA wants
FDA asks the firm to stop activities that cause misbranding or adulteration. Within 15 working days of receipt, the firm must notify FDA in writing of specific corrective steps, related documentation, and steps to prevent recurrence; if not complete, state the reason and completion date.
Who should pay attention
- laboratories and test providers offering at-home HIV collection kits
- companies selling or distributing self-collection diagnostic devices
- regulatory teams at diagnostic labs and kit manufacturers
This is a summary. Read the original letter on fda.gov.